Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decadesthere have been no concrete developments in their systemic treatment. In this trial we aimed to present ourosteosarcoma patient clinical and demographic outcomes. Materials and
Methods: Patients treated and followedup for osteosarcoma in Ankara Numune Education and Research Hospital from 2002 to 2012 were reviewedretrospectively.
Results: A total of 21 patients (15 male, 6 female) were diagnosed with osteosarcoma. The diseasewas located at extremities in 76% and in 14% was metastatic at the time of diagnosis. Median disease free survival(DFS) was 36 months in non-metastatic patients and median progression free survival (PFS) was 2 months inmetastatic patients (p<0.0001). Median overall survival (OS) was 80 months and 4 months, respectively (p=0.012).There were no survival differences in terms of presentation with pathological fracture, tumor size, tumor grade,alkaline phosphatase and lactate dehydrogenase level and type of chemotherapy regimen.
Conclusions: Tumorsite and stages are the most important prognostic factors for osteosarcoma. Extremity primary tumors have betersurvival rates than non-extremity tumors. As a result of the use of effective chemotherapy the long term survivalrates have improved from 10-20% to 60-70% in the last decades but we need more active agents, especially formetastatic cases.